Most Recent
Generic pharmaceutical company Aspen Pharma has resolved a patent infringement case brought by the maker of the anti-depressant Lexapro, according to a Federal Court order Tuesday.
A judge has granted F. Hoffman La-Roche's request for a temporary order blocking Sandoz from making or selling a biosimilar version of its patented biologic used to treat various cancers and rheumatoid arthritis.
GlaxoSmithKline is pushing for lower penalties in a case brought by the Australian Competition and Consumer Commission alleging the pharma giant breached the Australian Consumer Law in the marketing for its Voltaren Osteo Gel and Voltaren Emulgel pain relief products.
Three generic drug manufacturers cannot claim damages for an injunction barring the release of cheaper versions of Effexor-XR, even if the injunction was later overturned, pharmaceutical giant Wyeth told a judge on day two of a six-week trial over its blockbuster antidepressant.
The High Court has rejected a bid by biopharmaceutical company Samsung Bioepis Australia to challenge a ruling granting Pfizer preliminary discovery for a potential patent infringement case over autoimmune drug Enbrel.
Pharmaceutical giant Wyeth's has launched an "ambush" at the beginning of a trial after a nine-year long battle against several generic drug makers, alleging infringement of a second patent for its blockbuster Effexor-XR, a judge heard Monday.
A decade-long courtroom battle over a patent for Effexor-XR that delayed the release of cheap versions of the anti-depressant is at the centre of a trial starting Monday in Sydney pitting four generic drug makers against pharmaceutical giant Wyeth.
Generic drug giant Actavis Global has reached a settlement with AstraZeneca in a long-running patent dispute over blockbuster cholesterol medicine Crestor that wound its way to the High Court.
A judge has vacated a trial scheduled to start next week in Melbourne between the ACCC and NIB Health Funds over claims the health insurer violated consumer protection laws by making changes to its plans without first notifying members.
In a major loss for the ACCC, the Full Federal Court on Friday tossed the competition regulator's challenge to a ruling that drug giant Pfizer did not misuse its market power in the months leading up to the expiration of the patent for its blockbuster cholesterol drug Lipitor.